A modified release formulation of viloxazine consisting of viloxazine as active pharmaceutical ingredient, wherein said formulation comprises at least one of an extended release component and a delayed release component, wherein said extended release component comprises a core comprising viloxazine, and a coating of a release rate controlling compound on top of the core(s), and at least one pharmaceutically acceptable excipient, wherein the delayed release component comprises a core comprising viloxazine and a coating of an enteric compound on top of the core(s), and wherein enteric compound refers to a compound having solubility that is pH-dependent, and wherein the enteric compound is selected from a group consisting of poly (methyl acrylate-co-methyl methacrylate-co-methacrylic acid), poly (methacrylic acid-co-methyl methacrylate), hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, shellac, zein, wherein the release rate controlling compound is a hydrophilic compound selected from the group consisting of hydroxypropyl cellulose; hydroxypropyl methyl cellulose; methyl cellulose; polyethylene oxide; acacia; acrylic acid derivatives; alginic acid and its salts; hydroxyethyl cellulose; povidone; carrageenan; carboxymethylcellulose; tragacanth; polyvinyl alcohol; xanthan gum, and combinations thereof, or a hydrophobic compound selected from the group consisting of ethylcellulose; cellulose acetate; cellulose acetate butyrate; waxes; hydrogenated vegetable oils; glyceryl behenate; glyceryl palmitostearate; PEG glyceryl esters; poly(ethyl acrylate-co-methyl methacrylate) ethyl acrylate methyl methacrylate copolymer; poly (ethyl acrylate-co-methyl methacrylate-cotrimethylammonioethyl methacrylate chloride); polyvinyl acetate; cellulose acetate propionate, and combinations thereof; wherein the formulation comprises from 5% (w/w) to 65 % (w/w) of the release rate controlling compound, from 5% (w/w) to 50% (w/w) of the enteric compound, and 25% (w/w) to 75% (w/w) of viloxazine. wherein said extended release component comprises a core comprising viloxazine, and a coating of a release rate controlling compound on top of the core(s), and at least one pharmaceutically acceptable excipient, wherein the delayed release component comprises a core comprising viloxazine and a coating of an enteric compound on top of the core(s), and wherein enteric compound refers to a compound having solubility that is pH-dependent, and wherein the enteric compound is selected from a group consisting of poly (methyl acrylate-co-methyl methacrylate-co-methacrylic acid), poly (methacrylic acid-co-methyl methacrylate), hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, shellac, zein, wherein the release rate controlling compound is a hydrophilic compound selected from the group consisting of hydroxypropyl cellulose; hydroxypropyl methyl cellulose; methyl cellulose; polyethylene oxide; acacia; acrylic acid derivatives; alginic acid and its salts; hydroxyethyl cellulose; povidone; carrageenan; carboxymethylcellulose; tragacanth; polyvinyl alcohol; xanthan gum, and combinations thereof, or a hydrophobic compound selected from the group consisting of ethylcellulose; cellulose acetate; cellulose acetate butyrate; waxes; hydrogenated vegetable oils; glyceryl behenate; glyceryl palmitostearate; PEG glyceryl esters; poly(ethyl acrylate-co-methyl methacrylate) ethyl acrylate methyl methacrylate copolymer; poly (ethyl acrylate-co-methyl methacrylate-cotrimethylammonioethyl methacrylate chloride); polyvinyl acetate; cellulose acetate propionate, and combinations thereof; wherein the formulation comprises from 5% (w/w) to 65 % (w/w) of the release rate controlling compound, from 5% (w/w) to 50% (w/w) of the enteric compound, and 25% (w/w) to 75% (w/w) of viloxazine. <EOS>